STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAIA
  4. [Form 4] MAIA Biotechnology, Inc. Insider Trading Activity

MAIA Biotechnology (NASDAQ: MAIA) director granted 27,610 stock options at $1.44 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MAIA Biotechnology director Cristian Luput received a grant of stock options as equity compensation. He was awarded 27,610 stock options on the company’s common stock at an exercise price of $1.44 per share. The options vest 100% on the grant date and are immediately exercisable, giving him the right to buy up to 27,610 shares of common stock. Following this grant, his directly held stock option position reported in this filing totals 27,610 options, which remain outstanding until their stated expiration in 2036.

Positive

  • None.

Negative

  • None.
Insider Luput Cristian
Role null
Type Security Shares Price Value
Grant/Award Stock Options 27,610 $0.00 --
Holdings After Transaction: Stock Options — 27,610 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Stock options granted 27,610 options Grant to director on June 30, 2026
Exercise price $1.44 per share Strike price for granted stock options
Options outstanding after grant 27,610 options Total stock options held following transaction
Grant vesting 100% on grant date Immediate vesting per footnote
Option expiration June 30, 2036 Expiration date of stock options
Stock Options financial
"The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
2021 Equity Incentive Plan financial
"granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"
vest 100% on the date of the grant financial
"representing the right to buy shares of common stock, vest 100% on the date of the grant"
exercise price financial
"conversion_or_exercise_price": "1.4400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Luput Cristian
(Last)(First)(Middle)
444 WEST LAKE STREET, SUITE 1700
(Street)
CHICAGO ILLINOIS 60606
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options$1.4406/30/2026A27,61006/30/2026(1)06/30/2036Common Stock27,610$027,610D
Explanation of Responses:
1. The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
/s/ Cristian Luput07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did MAIA (MAIA) director Cristian Luput report in this Form 4 filing?

Director Cristian Luput reported receiving a grant of 27,610 stock options on MAIA Biotechnology common stock. These options were granted as equity compensation, vest immediately on the grant date, and are exercisable at a fixed price of $1.44 per share until 2036.

How many MAIA (MAIA) stock options were granted to Cristian Luput and at what price?

Cristian Luput was granted 27,610 stock options with an exercise price of $1.44 per share. Each option represents the right to buy one share of MAIA Biotechnology common stock, providing potential future share ownership at that fixed price.

When do Cristian Luput’s MAIA (MAIA) stock options vest and become exercisable?

The stock options granted to Cristian Luput vest 100% on the date of grant and are exercisable beginning as of that date. This means he does not face a waiting period and can choose to exercise the options immediately after receiving them.

What is the expiration date of the MAIA (MAIA) stock options granted to Cristian Luput?

The options granted to Cristian Luput expire on June 30, 2036. Up to that date, he may exercise the options to purchase MAIA Biotechnology common shares at $1.44 per share, subject to the terms of the 2021 Equity Incentive Plan.

Are Cristian Luput’s MAIA (MAIA) option grants an open-market stock purchase?

No, these are not open-market stock purchases. The filing shows a compensation-related grant of 27,610 stock options under MAIA Biotechnology’s 2021 Equity Incentive Plan, giving him the right to buy shares at a preset $1.44 exercise price.